Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge

Microbes and Infection

Volumn 15, Issue 13, 2013, Pages 920-927

  Tifrea, Delia F ^a   Pal, Sukumar ^a   Toussi, Deana N ^b   Massari, Paola ^b   de la Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chlamydia; Detergents; Major outer membrane protein; Mouse model; Proteosomes; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; OUTER MEMBRANE PROTEIN; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELLULAR IMMUNITY; CHLAMYDIA; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; IMMUNE RESPONSE; LUNG INFECTION; LUNG WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION; WEIGHT CHANGE;

ANIMALIA; CHLAMYDIA; CHLAMYDIA MURIDARUM; MUS;

CHLAMYDIA; DETERGENTS; MAJOR OUTER MEMBRANE PROTEIN; MOUSE MODEL; PROTEOSOMES; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MANNITOL; MICE; OLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; PNEUMONIA, BACTERIAL; VACCINATION;

EID: 84888050108     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.08.005     Document Type: Article

References (45)

1. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 2005, 5:149-161.
2. Stamm W. Chlamydia trachomatis infections of the adult. Sexually Transmitted Diseases 2008, 575-593. McGrawHill Book Co, New York. K.K. Holmes PS, W.E. Stamm, P. Piot, J.W. Wasserheit, L. Corey, M.S. Cohen, D.H. Watts (Eds.).
3. Schachter J., Dawson C.R. Human Chlamydial Infections 1978, PSG Pub. Co, Littleton, Mass.
4. Stutman H.R., Rettig P.J., Reyes S. Chlamydia trachomatis as a cause of pneumonitis and pleural effusion. J. Pediatr. 1984, 104:588-591.
5. Wang S.P., Grayston J.T., Alexander E.R. Trachoma vaccine studies in monkeys. Am. J. Ophthalmol. 1967, 63(Suppl):1615-1630.
6. Taylor H.R. Trachoma: A Blinding Scourge from the Bronze Age to the Twenty-first Century 2008, Haddington Press Pry Ltd, Victoria, Australia.
7. Wang S.P., Grayston J.T. Classification of trachoma virus strains by protection of mice from toxic death. J. Immunol. 1963, 90:849-856.
8. Morrison R.P., Lyng K., Caldwell H.D. Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein. J. Exp. Med. 1989, 169:663-675.
9. Rockey D.D., Wang J., Lei L., Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev. Vaccines 2009, 8:1365-1377.
10. de la Maza L.M., Peterson E.M. Vaccines for Chlamydia trachomatis infections. Curr. Opin. Invest. Drugs 2002, 3:980-986.
11. Nikaido H. Porins and specific channels of bacterial outer membranes. Mol. Microbiol. 1992, 6:435-442.
12. Sun G., Pal S., Sarcon A.K., Kim S., Sugawara E., Nikaido H., Cocco M.J., Peterson E.M., de la Maza L.M. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J. Bacteriol. 2007, 189:6222-6235.
13. Pal S., Peterson E.M., de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 2005, 73:8153-8160.
14. Blake M.S., Wetzler L.M. Vaccines for gonorrhea: where are we on the curve?. Trends Microbiol. 1995, 3:469-474.
15. Tifrea D.F., Sun G., Pal S., Zardeneta G., Cocco M.J., Popot J.L., de la Maza L.M. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine 2011, 29:4623-4631.
16. Castro C.A., Hogan J.B., Benson K.A., Shehata C.W., Landauer M.R. Behavioral effects of vehicles: DMSO, ethanol, tween-20, tween-80, and emulphor-620. Pharmacol. Biochem. Behav. 1995, 50:521-526.
17. Speijers G.J., Danse L.H., Beuvery E.C., Derks H.J., Vos J.G. Local reactions of zwittergent-containing meningococcal vaccine after intramuscular injection in rats: comparison with the effect of diphtheria-pertussis-tetanus-polio vaccine. Vaccine 1988, 6:419-422.
18. Massari P., Ram S., Macleod H., Wetzler L.M. The role of porins in neisserial pathogenesis and immunity. Trends Microbiol. 2003, 11:87-93.
19. Lowell G.H., Ballou W.R., Smith L.F., Wirtz R.A., Zollinger W.D., Hockmeyer W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 1988, 240:800-802.
20. Lowell G.H., Smith L.F., Seid R.C., Zollinger W.D. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med. 1988, 167:658-663.
21. Herrington D.A., Clyde D.F., Losonsky G., Cortesia M., Murphy J.R., Davis J., Baqar S., Felix A.M., Heimer E.P., Gillessen D., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328:257-259.
22. Toussi D.N., Liu X., Massari P. The FomA porin from Fusobacterium nucleatum is a toll-like receptor 2 agonist with immune adjuvant activity. Clin. Vaccine Immunol. 2012, 19:1093-1101.
23. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 1981, 31:1161-1176.
24. Massari P., Toussi D.N., Tifrea D.F., de la Maza L.M. Toll-like receptor 2-dependent activity of Chlamydia trachomatis native major outer membrane protein proteosomes of Chlamydia trachomatis. Infect. Immun. 2013, 81:303-310.
25. Sun G., Pal S., Weiland J., Peterson E.M., de la Maza L.M. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 2009, 27:5020-5025.
26. Pal S., Davis H.L., Peterson E.M., de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect. Immun. 2002, 70:4812-4817.
27. Pal S., Fielder T.J., Peterson E.M., de la Maza L.M. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 1994, 62:3354-3362.
28. Farris C.M., Morrison S.G., Morrison R.P. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect. Immun. 2010, 78:4374-4383.
29. Morrison R.P., Caldwell H.D. Immunity to murine chlamydial genital infection. Infect. Immun. 2002, 70:2741-2751.
30. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., Peterson E.M., Pal S., de la Maza L.M., Caldwell H.D. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 2009, 182:8063-8070.
31. Igietseme J.U., Ramsey K.H., Magee D.M., Williams D.M., Kincy T.J., Rank R.G. Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg. Immunol. 1993, 5:317-324.
32. Hansen J., Jensen K.T., Follmann F., Agger E.M., Theisen M., Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis. 2008, 198:758-767.
33. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18:1755-1762.
34. Hirunpetcharat C., Wipasa J., Sakkhachornphop S., Nitkumhan T., Zheng Y.Z., Pichyangkul S., Krieg A.M., Walsh D.S., Heppner D.G., Good M.F. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based montanides. Vaccine 2003, 21:2923-2932.
35. Miles A.P., McClellan H.A., Rausch K.M., Zhu D., Whitmore M.D., Singh S., Martin L.B., Wu Y., Giersing B.K., Stowers A.W., Long C.A., Saul A. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005, 23:2530-2539.
36. Saul A., Lawrence G., Allworth A., Elliott S., Anderson K., Rzepczyk C., Martin L.B., Taylor D., Eisen D.P., Irving D.O., Pye D., Crewther P.E., Hodder A.N., Murphy V.J., Anders R.F. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in montanide ISA720 adjuvant. Vaccine 2005, 23:3076-3083.
37. Morrison S.G., Morrison R.P. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect. Immun. 2001, 69:2643-2649.
38. Williams D.M., Schachter J., Drutz D.J., Sumaya C.V. Pneumonia due to Chlamydia trachomatis in the immunocompromised (nude) mouse. J. Infect. Dis. 1981, 143:238-241.
39. Finco O., Frigimelica E., Buricchi F., Petracca R., Galli G., Faenzi E., Meoni E., Bonci A., Agnusdei M., Nardelli F., Bartolini E., Scarselli M., Caproni E., Laera D., Zedda L., Skibinski D., Giovinazzi S., Bastone R., Ianni E., Cevenini R., Grandi G., Grifantini R. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9969-9974.
40. Yu H., Jiang X., Shen C., Karunakaran K.P., Brunham R.C. Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models. J. Immunol. 2009, 182:1602-1608.
41. Toussi D.N., Carraway M., Wetzler L.M., Lewis L.A., Liu X., Massari P. The amino acid sequence of Neisseria lactamica PorB surface-exposed loops influences toll-like receptor 2-dependent cell activation. Infect. Immun. 2012, 80:3417-3428.
42. Zhu W., Chen C.J., Thomas C.E., Anderson J.E., Jerse A.E., Sparling P.F. Vaccines for gonorrhea: can we rise to the challenge?. Front Microbiol. 2011, 2:124.
43. Zhu W., Thomas C.E., Chen C.J., Van Dam C.N., Johnston R.E., Davis N.L., Sparling P.F. Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles. Infect. Immun. 2005, 73:7558-7568.
44. de la Maza M.A., de la Maza L.M. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 1995, 13:119-127.
45. Farris C.M., Morrison R.P. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect. Immun. 2011, 79:986-996.